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Abstract
Purpose. Diabetic patients have a high risk for cardiovascular events. The role of 
myocardial perfusion imaging was investigated in asymptomatic diabetic patients to 
evaluate short-term prognosis in a Japanese population.
Methods. A total of 506 asymptomatic patients ≥50 years of age who had carotid 
artery maximum intima-media thickness ≥1.1mm, urinary albumin excretion of ≥30mg/
g creatinine, with additional criteria of abdominal obesity, low HDL cholesterol, high 
triglyceride level and hypertension were enrolled and followed up  over a3-year period. 
Gated SPECT with stress-rest protocol was performed and analyzed by  summed defect 
scores and QGS software. One-year cardiovascular events were analyzed.
Results. Myocardial ischemia was observed in 17% of patients, and abnormal 
perfusion findings of ischemia and/or scar were observed in 32% of patients. By the end 
of the one-year follow-up, 33 (6.5%) cardiovascular events occurred including 6 all-
cause deaths. Patients with summed stress score (SSS) >8 had a higher incidence of 
either death or cardiovascular events. Event-free survival rates for SSS 0-3, 4-8, 9-13 
and ≥14 were 0.96, 0.95, 0.82 and 0.76, respectively. Multivariate Cox regression 
analysis showed that significant variables were SSS, history of cerebrovascular accident 
and electrocardiographic abnormality at rest.
Conclusions. The one-year interim summary showed that cardiovascular events were 
significantly higher in patients with SPECT abnormality, although hard cardiac event 
rate was relatively  low. Targeted treatment strategy is required for asymptomatic but 
potentially high-risk diabetic patients.
Key words
Asymptomatic diabetes mellitus, coronary artery disease, gated myocardial perfusion 
imaging, 99mTc-tetrofosmin, prognosis
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Introduction 
For risk stratification of ischemic heart events, coronary stenosis, myocardial ischemia 
and baseline cardiac functions are important  factors to predict patient prognosis. Various clinical 
conditions including metabolic syndrome have been investigated using myocardial perfusion 
imaging (MPI). [1] Among the clinical backgrounds, diabetes mellitus promotes atherosclerosis, 
resulting in one of the major pathophysiological causes of cerebral infarction and myocardial 
infarction. [2-4] The risk of patients with diabetes are two- to fourfold higher than non-diabetic 
patients and are comparable with those with prior myocardial infarction. [5, 6] Since 
atherosclerosis may progress even in asymptomatic diabetic patients, it is vital to diagnose 
ischemic heart diseases at an early subclinical stage. [7-9]
 The role of MPI for detecting ischemia has been validated well and supported by many 
precedent  single-photon emission computed tomography (SPECT) studies. [10-13] A general 
consensus has been achieved for detection of ischemia and prognostic evaluation. [3, 14] 
Although abundant data are available in Western countries, few data are available dealing with 
the role of MPI in Japanese non-diabetic and diabetic patients. In a Japanese prognostic cohort 
study using gated SPECT (J-ACCESS study), the hard event rate was relatively lower than that 
in Western prognostic studies. [6, 15] We therefore began the J-ACCESS 2 prospective cohort 
study with a three-year follow-up period that focused on asymptomatic patients with type 2 
diabetes. 
We hypothesized that gated MPI has prognostic values to predict  cardiovascular 
events even in a short-term follow-up. The incidences of stress-induced ischemia and resting 
perfusion defect, as well as functional abnormalities by gated MPI, were summarized in 




 The J-ACCESS II prognostic registry was a prognostic cohort  study involving 513 
patients from 50 institutions. [16] The registration period was from June 2004 through 
September 2005. All institutions employed certified physicians for diabetes and could 
participate in a 3-year follow-up after registration. The inclusion criteria included patients with 
type 2 diabetes, ≥50 years of age, who either had a maximal carotid artery intima-media 
thickness (max IMT) ≥ 1.1 mm by ultrasonography or a urinary albumin excretion rate of ≥30 
mg/g creatinine, or patients who satisfied at  least  two of the following four conditions: 
abdominal obesity (body mass index (BMI) ≥ 25 and waist circumference ≥85 cm for men, and 
≥90 cm for women) hypo-HDL-cholesterolemia (<40 mg/dL); hypertriglyceridemia (≥150 mg/
dL), and hypertension (blood pressure ≥ 130/85 mmHg) (Figure 1). The criteria of waist 
circumference were in accordance with Japanese guidelines. [17, 18] Exclusion criteria included 
patients with myocardial infarction, effort angina and unstable angina. Patients with HbA1c 
≥10% or evidence of nephropathy (serum cr.
eatinine ≥1.5 mg/dL) within 1 month before enrollment were excluded. Also excluded were 
patients with valvular heart disease, idiopathic cardiomyopathy, evidence of rest ECG 
abnormalities such as atrial fibrillation, New York Heart  Association Class III or IV heart failure 
at  the time of myocardial perfusion SPECT and arteriosclerosis obliterans. A total of 83% of 
patients were medically treated, and the remaining patients were controlled by diet, exercise, 
etc. at the time of registration.
 Each hospital approved the study by the institutional review board, and the whole 
study was conducted in compliance with the Ethical Guidelines For Epidemiological Research 
in Japan. Written informed consent was obtained from all participants. 
Myocardial perfusion imaging
Stress-rest  MPI was performed with 99mTc-tetrofosmin. A 1-day protocol was used in 
94% of the institutions, and a two-day protocol in the remaining institutions. Regarding the 
stress types, exercise, dipyridamole (0.15 ml/min/kg x 4 min), adenosine (0.12 ml/min/kg x 6 
min) and adenosine triphosphate (0.16 ml/min/kg x 5 min) were performed in 72%, 16%, 6% 
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and 6% of the institutions, respectively. The average dose of 99mTc-tetrofosmin administered 
was 331 MBq for the initial study and 748 MBq for the second study. The exercise study was 
performed at 36±20 minutes after tetrofosmin injection, and the resting study was similarly 
performed at  47±20 minutes after injection. The interval between the stress and rest studies was 
60-120 minutes. A gated study was performed at least at  rest. SPECT imaging was performed 
with standard acquisition protocols with 360 or 180-degree rotations. Gating was performed by 
16, 8, 12 and 32 frames per cardiac cycle in 44%, 40%, 12% and 4% of the institutions. 
According to the preceding J-ACCESS substudy in patients with low-likelihood of ischemic 
heart  disease and no events, EF with the 16-frame study was significantly higher than that with 
the 8-frame study by 4% only in men.[19]
Myocardial segmentation and quantification
Myocardial perfusion images of short-axis, vertical long-axis and horizontal long-axis 
images were generated with a standard acquisition protocol, which was verified by J-ACCESS 
study. [6, 19, 20] All SPECT images were interpreted using a 20-segment  model by experienced 
physicians. The use of 20-segment model was to compare results with the precedent J-ACCESS 
study, which showed good correlation with 17-segment  model. [21] Each of the myocardial 
segments was visually scored using a 5-point  scoring system: 0= normal, 1=mildly reduced, 
2=moderately reduced, 3=severely reduced and 4=absent. Total scores in 20 segments were 
calculated as the sum of stress, rest and difference scores (SSS, SRS and SDS). Four SSS 
severity categories were used for risk-based groups of 0-3 (normal), 4-8 (mild), 9-13 (moderate) 
and ≥14 (severe).
 Procedures for quantification of gated SPECT  are described elsewhere [6, 20]. Gated 
SPECT was analyzed by QGS software (Cedars Sinai Medical Center, CA, USA) of each 
institution.[19] Manual adjustment was performed when automatic edge tracing was 
inappropriate. The left  ventricular ejection fraction (LVEF, %), end-diastolic volume (EDV, 
mL), and end-systolic volume (ESV, mL) were obtained. 
Follow-up survey
     The cardiovascular events were investigated at  1, 2, and 3 years after the registration, and 
this interim report  was based on the results of the one-year follow-up. Follow-up was completed 
in 100% of the patients by the end of one year. After excluding 7 patients who had early 
revascularization <30 days of registration, 506 patients were finally selected for prognostic 
analysis. Events of all-cause death and non-fatal acute coronary syndrome were defined as hard 
events. Total events further included the percutaneous coronary intervention (PCI), coronary 
artery bypass grafting (CABG), de novo stable angina, unstable angina, severe heart failure 
requiring hospitalization, transient ischemic attack of the brain, stroke and arteriosclerosis 
obliterans. 
Statistics
Continuous variables are expressed as mean ± standard deviation (SD). We applied 
the Wilcoxon rank sum test to compare results from patients with and without cardiac events, 
and the χ2 test to categorical data. The differences in cardiovascular event rates among SSS 
severity groups were compared using Kaplan-Meier estimates. The independent variables in 
the univariate Cox proportional hazard model included age, gender, cardiac risk factors, 
summed scores, QGS parameters of EF and volumes. The relative hazard ratios, 95% 
confidence intervals and Wald χ2 values were calculated. The multivariate Cox proportional 
model was applied using a forward stepwise method based on selected independent variables 
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Among the criteria for patient registry, the criteria of maximum IMT  ≥1.1 mm and 
urinary albumin excretion rate of ≥30 mg/g of creatinine, were satisfied in 37% and 35 % of 
patients, respectively.  
 Table 1 shows patient  characteristics in 506 subjects. Common risk factors were 
hypertension (82%) and dyslipidemia (80%).  Regarding other risk factors, 17% and 26 % of 
patients had current and past  smoking, respectively, and 6% had family history of CAD.  BMI 
of ≥30 kg/m2 was observed in 40 (8%) patients. Regarding medications, hypoglycemic drugs 
were most  often used (83%). Coronary angiography was performed in 45 patients (9%). 
Coronary artery stenosis ≥75% was observed in 19 patients: single, double and triple-vessel 
diseases in 9, 8, and 2 patients, respectively.
SPECT findings of perfusion defects and ischemia
Myocardial ischemia without fixed defects (scarring) defined as SDS ≥2 and SRS<4 
was observed in 54 patients (11%), and fixed perfusion defect without  ischemia defined as SRS 
≥4 and SDS <2 was observed in 80 patients (16%) (Figure 1). Fixed perfusion defect  associated 
with ischemia defined as SRS ≥4 and SDS ≥2 was observed in 30 patients (6%). The remaining 
normal findings were observed in 342 patients (68%).  Stress-induced ischemia with and 
without scarring was observed in 84 patients (17%).
Death and cardiovascular events by the end of one year
During the one-year follow-up period, 6 patients died, including 2 from sudden death, 
1 from severe heart  failure and double-vessel disease, 2 from cancer and 1 from complication of 
pneumonia (Table 2). One of the cancer patients experienced stable angina and PCI before 
death. Two patients who showed EF <50% had severe heart failure; one died and the other had 
CABG.
Regarding non-fatal cardiovascular events, de novo stable angina pectoris was 
diagnosed in 11 patients, of whom 8 of them had PCI, and the remaining patients were 
medically treated. Either cerebrovascular accident or transient  ischemia attack was observed in 
7 patients. PCI was performed in 12, CABG in 1 and both PCI and CABG in 1. 
The following events were summarized based on all-cause death and non-fatal 
cardiovascular events. Patients with and without events are compared in Table 3. Patients with 
events had a significantly higher incidence of ECG abnormality at rest  (p=0.02) and significant 
coronary stenosis (≥75%) in at  least  one vessel than those without events (24% vs. 2%, 
p=0.005). Regarding medication, in patients with events, medications for dyslipidemia were less 
frequent  in the event group (p=0.03). Although EF and volumes did not differ significantly, 
patients with cardiac events showed higher SSS (p=0.005) and SDS (p=0.02). When patients 
with SSS ≤8 and >8 were compared, cardiac event  rates were 5% for the low SSS group and 
20% for the high SSS group (p=0.0002). The high SSS group showed a higher LDL cholesterol 
(p=0.03), a lower incidence of dyslipidemic medication (p=0.02), a higher blood urea nitrogen 
(p=0.04), a higher urinary albumin excretion rate (p=0.02) and a higher incidence of segmental 
wall motion abnormality (p=0.009). Myocardial perfusion defect scores of SRS and SDS were 
higher in the high SSS group (p<0.0001 for all). The higher EDV, higher ESV and lower EF 
were observed in the high SSS group (p<0.0001 for all).
The Kaplan-Meier curve for the event-free survival is shown in Figure 2. At  the end of 
the 1-year follow-up, the event-free rate was 0.96, 0.95, 0.82 and 0.76 for the SSS group of 0-3, 
4-8, 9-13 and 14 or more, respectively. Since the curves were divided into two groups of SSS <8 
and >8 and differed significantly (p<0.0001), the following analysis was performed using two 
groups of high and low SSS values.
Univariate analysis showed that the significant  variables were HDL cholesterol, blood 
urea nitrogen, creatinine, ECG abnormality at rest, significant coronary stenosis, SRS, SDS and 
SSS (Figure 3). When the multivariate Cox regression analysis was applied, SSS (>8 vs. ≤8, 
χ2=16.9, p<0.0001), rest ECG abnormality (χ2=6.1, p=0.013) and cerebrovascular accident 
(χ2=5.7, p=0.017) were the independent predictor of cardiovascular events, but  the HDL 
cholesterol was not selected as a significant predictor.
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Discussion
In the J-ACCESS 2 population with asymptomatic type 2 diabetes, which was strictly 
defined by the selection criteria of carotid maximum IMT, microalbuminuria, abdominal 
obesity, dyslipidemia and hypertension, stress-induced ischemia was observed in 17% of 
patients. The cardiovascular event  rate was four-fold higher in high-SSS patients (>8) than in 
low-SSS (≤8) patients. The total event rate was 33 of 506 (6.5%) including 6 deaths (1.2%). 
Patients with events had higher SSS and SDS, ECG abnormality at  rest  and significant  coronary 
artery stenosis found by coronary angiography than those without.
Among patients with diabetes, CAD is a leading cause of death, as well as extensive 
deterioration of macrovascular and microvascular components of multiple organs.  The 
prevalence of diabetes in the Japanese population, however, has been considered to be lower 
than that in Western population, but it is rapidly increasing with westernizing lifestyles, as 
revealed by recent epidemiological surveys of Hisayama and the Japanese Diabetes Society. 
[22-24] Therefore, by recognizing the differences in baseline lifestyles between Western and 
Japanese populations, the cardiovascular event  rate in Japanese asymptomatic diabetic patients 
was of great concern.
The high prevalence of diabetes was also confirmed by the J-ACCESS study, which 
included 30% of diabetic patients by consecutive registration of 4629 patients. [6] The impact  of 
diabetes was equivalent  to that  of prior myocardial infarction when the cardiac major cardiac 
event  rate of cardiac death, non-fatal myocardial infarction and severe heart failure requiring 
hospitalization was analyzed. The finding in the Japanese population was in accordance with the 
study by Haffner et al. and also consistent with a statement "diabetes is a cardiovascular 
disease" by the American Heart Association. [5, 25] 
 A high incidence of abnormal scans has been noted in asymptomatic patients. Miller et 
al. found that abnormal scans were present in ~60% of asymptomatic diabetic patients, 
approximately equal to the percentage in symptomatic diabetic. [26] In addition, a DIAD study 
indicated silent myocardial ischemia occurred in as high as 22% of asymptomatic patients with 
type 2 diabetes. [27] In another European study involving 120 asymptomatic patients, 33% had 
an abnormal stress study, including myocardial perfusion abnormalities in 25% of patients. [28] 
The present J-ACCESS 2 study demonstrated a relatively lower incidence (17%) of induced 
ischemia. This was probably caused by the difference in criteria of patient entry, and partly due 
to baseline ethnic differences among America, European and Japanese populations. 
The incidence of ischemia and cardiovascular events is thought to be influenced by the 
selection criteria. Screening all diabetic patients is not justified from a practical point  of view. It 
is imperative to identify the best candidate for screening diabetic patients to obtain the high 
diagnostic yield from MPI. [29] In the DIAD study, careful exclusion criteria were used to avoid 
the possibility of ischemic heart diseases, namely to select truly asymptomatic patients. In the J-
ACCESS 2 study, to register the patients with appropriate diagnostic yields, we decided to 
select the patients who had metabolic status of possible ischemia, although they had no chest 
symptom and evidence of CAD at the time of entry. The DIAD study patients showed a mean 
HbA1c of 7.1±1.5%, LDL cholesterol of 113±32 mg/dL and 85% of either insulin or oral agent 
treatment, whereas the J-ACCESS II showed 7.5±1.2%, 118±31 mg/dL and 83%, respectively. 
Moreover, BMI was higher in the DIAD study (31±6 kg/m2) than in the J-ACCESS 2 study 
(25±4 kg/m2). Albuminuria of >30 mg/g creatinine was observed in 21% of the patients in the 
DIAD study, whereas in the J-ACCESS 2 study the average albuminuria was 175±505 mg/g. 
J-ACCESS 2 study demonstrated that  significant predictors of cardiovascular events 
were defect score during stress, rest  ECG abnormality and cerebrovascular accidents by 
multivariate analysis. In contrast, Scholte et al. demonstrated that current  smoking, duration of 
diabetes and the cholesterol/HDL ratio to predict  an abnormal study. [28] During their one-year 
follow-up, 5% (6 of 120) had cardiac events. Although the predictors may differ between the 
studies, our study endpoint was cardiovascular events, not  perfusion abnormality. Our study 
showed a comparable event rate of 6.5% (33 of 506) to this European study. In the J-ACCESS 2 
population, LDL cholesterol differed between high and low SSS groups, but  the event  rates did 
not differ significantly between them. The event  group, however, showed a tendency of lower 
HDL cholesterol (p=0.06). Smoking was not significant predictors for ischemia and cardiac 
events in this study and preceding J-ACCESS study with regards to major cardiac events and 
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total events. [6, 15]
The outcome of the diabetic patient  with SPECT abnormality was worse than those 
without  SPECT abnormality. A study of asymptomatic diabetic patients without known CAD 
demonstrated a 2.2% annual critical event  rate of myocardial infarction and cardiac deaths. [30] 
Another study demonstrated that  8.6% of patients with diabetes had cardiac events (cardiac 
deaths and myocardial infarction) compared with 4.5% in the nondiabetic cohort. [12] The 
critical event  rate seemed lower in our study as long as one-year interim results were observed. 
Even in our study, however, the incidence of sudden death, PCI, CABG, severe heart  failure was 
in 3.6% of asymptomatic patients and cerebrovascular accident and transient ischemic attack in 
1.4%. Interestingly, Wackers et  al. found that  majority of asymptomatic patients with type 2 
diabetes demonstrated resolution of ischemia on repeat stress imaging after 3 years.[31] 
Therefore, appropriate or aggressive management  of these patients would modify the outcome, 
and further follow-up has continued for three years in our study group. 
Conclusion
 When asymptomatic diabetic patients were followed up in a Japanese population, the 
incidence of cardiovascular events with SPECT abnormality was higher than that  without 
SPECT abnormality even in the one-year interim summary. To avoid potential outcome of hard 
events in these patients, targeted efforts would be required for those who have clinical 
conditions of micro-albuminuria, increased carotid max IMT, dyslipidemia, hypertension and 
abdominal obesity. 
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Figure Legends
Figure 1
Study design of J-ACCESS 2 and results of myocardial perfusion imaging
Figure 2
Event-free survival in 4 severity groups: SSS 0-3 (n=363), 4-8 (n=93), 9-13 (n=33) and 
>13 (n=17). A significant difference was observed between groups between SSS 0-8 and 
SSS ≥9 (p<0.0001).
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Figure 3 Hazard ratios by univariate Cox regression analysis. Bars indicate the hazard 
ratio and 95% confidence intervals. P values <0.05 are shown.
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Table 1. Patient characteristics (n=506)
� number, mean±SD, %
Number of patients 506
Age (years), male gender (%) 67±8, 58%
Body weight (kg) 63±11
Body mass index (kg/m2) 25±4
Waist circumference (cm) 89±11




 Cerebrovascular accident 10%
 Family history of CAD 6%




 for diabetics (insulin use) 83% (30%)
 for hypertension 66%
 for dyslipidemia 41%
Biochemical data
 Total cholesterol (mg/dL) 200±35
 LDL cholesterol (mg/dL) 118±31
 HDL cholesterol (mg/dL) 51±15
 Triglyceride (mg/dL) 168±114
 Fasting blood sugar (mg/dL) 158±55
 Hemoglobin A1c (%) 7.5±1.2
 Blood urea nitrogen (mg/dL) 16.7±5.1
 Creatinine (mg/dL) 0.78±0.24
 Urinary microalbumin (mg/g Cre) 175±505 (range 0-5272)
ECG, echocardiography, coronary angiography
 ECG abnormality at rest 95/444 (21%)
 Ischemia on stress ECG 129/167 (67%)
 Wall motion abnormality 8/181 (4%)
 0, 1, 2, and 3 vessel diseases 26, 9, 8, 2
Nuclear study
 EDV (mL),  EDVI (mL/m2) 74±22, 44±11
 ESV (mL),  ESVI (mL/m2) 25±13, 15±7
 LVEF (%) 67%±10%
 SSS 2.7±4.3
 SRS 2.1±3.7 
 SDS 0.60±2.4
IMT, intima-media thickness; CAD, coronary artery disease
EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction
EDVI, end-diastolic volume index; ESVI, end-systolic volume index
SSS, summed stress score; SRS, summed rest score; SDS, summed difference score
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 Table 2. Death and cardiovascular events within a year
Events ? N Total
Death 6
Heart failure, 2VD 1
Stable Angina, PCI, cancer 1
Sudden death 1
Sudden death, 2VD 1
Cancer 1





Stable Angina, PCI 7
Stable Angina, ASO, PCI 1
Stable Angina 3





Total ? ? 33
VD, vessel disease; PCI, percutaneous coronary intervention; ACS, acute coronary syndrome, CABG, 
coronary artery bypass grafting; VSA, vasospastic angina; CVA, cerebrovascular accident; TIA, transient 
ischemic attack of the brain; ASO, arteriosclerosis obliterans
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Table 3. 




events No events p values SSS 0-8 SSS >8 p values
N 33 473 456 50
Cardiovascular events and 
death 5% 20% 0.0002
Age (years) 69±9 67±8 0.3 67±8 67±8 0.6
Male gender 58% 58% 1.0 43% 30% 0.09
Body mass index (kg/m2) 25±4 25±4 0.8 25±4 25±5 0.7
Maximum IMT (mm) 1.6±0.6 1.7±0.8 0.7 1.7±0.8 1.6±0.7 0.2
Complications
 Retinopathy 24% 26% 0.3 26% 20% 0.4
 Neuropathy 21% 20% 0.8 19% 26% 0.3
 Cerebrovascular accident 18% 10% 0.7 10% 12% 0.9
 Family history of CAD 3% 6% 0.3 5% 8% 0.6
Current smoking 24% 17% 1.0 17% 18% 1.0
Medications
 Medication for diabetics 94% 82% 0.1 83% 88% 0.4
 Insulin 42% 29% 0.2 29% 38% 0.3
 Medication for hypertension 82% 65% 0.08 66% 66% 1.0
 Medication for dyslipidemia 21% 42% 0.03 43% 24% 0.02
 Anti-platelet medication 42% 26% 0.06 26% 34% 0.3
Biochemical data
 Total cholesterol (mg/dL) 208±32 199±35 0.1 199±35 205±33 0.2
 LDL cholesterol (mg/dL) 122±27 117±31 0.3 117±31 130±29 0.03
 HDL cholesterol (mg/dL) 46±9 51±15 0.06 51±15 51±14 0.8
 Triglyceride (mg/dL) 181±104 167±115 0.5 169±118 155±77 0.7
 Fasting blood sugar (mg/dL) 163±66 158±54 0.8 158±55 161±56 0.4
 Hemoglobin A1c(%) 7.1±1.2 7.5±1.2 0.09 7.5±1.2 7.4±1.3 0.6
 Blood urea nitrogen (mg/dL) 19±6 16±5 0.08 16±5 18±5 0.04
 Creatinine (mg/dL) 0.85±0.31 0.78±0.23 0.3 0.78±0.23 0.84±0.29 0.2
 urinary albumin (mg/g Cre) 300±402 168±511 0.08 174±521 192±333 0.02
 Log [urinary albumin (mg/g 
Cre)] 4.7±1.7 3.9±1.4 0.08 3.9±1.5 4.5±1.2 0.02
ECG, echocardiography, coronary angiography
 ECG abnormality at rest 36% 18% 0.02 19% 20% 1.0
 Ischemia on stress ECG 12% 12% 1.0 12% 16% 1.0
 Wall motion abnormality 3% 1% 1.0 1% 8% 0.009
 1VD, 2VD, 3VD 24% 2% 0.005 2% 18% 0.6
Nuclear studies
 EDV (mL) 74±28 74±22 0.6 72±20 92±32 <0.0001
 ESV (mL) 26±16 25±13 0.9 24±12 37±19 <0.0001
 LVEF (%) 66±12 68±10 0.5 68±10 61±9 <0.0001
 SSS 5.5±6.0 2.5±4.0 0.005 - -
 SRS 3.3±4.7 2.0±3.6 0.2 1.3±2.2 9.2±6.0 <0.0001
 SDS 2.2±4.5 0.5±2.1 0.02 0.2±1.44 3.9±5.2 <0.0001
Abbreviations are the same as in Table 1 
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